Screener
Delcath Systems DCTH Q3 2026 earnings
Reported November 9, 2026 · Before market open
Revenue$35.1MBeat by $9.1M
EPS$0.17Beat by $0.26
Revenue estimate$26.0M
EPS estimate-$0.09
“We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development. Growing physician experience with HEPZATO, strong engagement across our treatment center network, and increasing interest in its use alongside systemic therapies reinforce our confidence in the long-term opportunity. We are also expanding our pipeline, with a planned IND submission for cholangiocarcinoma in early 2027 and, pending FDA agreement, completion of ongoing preclinical development of an oxaliplatin-based PHP product by mid-2027.”
Next report
Date not yet announcedValuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Delcath Systems report Q3 2026 earnings?
- Delcath Systems (DCTH) reported Q3 2026 earnings on November 9, 2026 before market open.
- What were Delcath Systems's Q3 2026 revenue and EPS?
- Delcath Systems reported revenue of $35.1M and eps of $0.17 for Q3 2026.
- Did Delcath Systems beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $26.0M by $9.1M. EPS beat the consensus estimate of $-0.09 by $0.26.
- How did Delcath Systems's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 70.7% from $20.6M a year earlier and eps grew 750.0% from $0.02.
- Where can I find Delcath Systems's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-071894) and the 10-Q periodic report (0001628280-26-071915) directly on SEC EDGAR. The filing index links above go to sec.gov.
